UNSPSC 51273606: Articaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C13H20N2O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QS9014Q792, chemically known as 2-thiophenecarboxylic acid, 4-methyl-3-(2-(propylamino)propionamido)-, methyl ester, monohydrochloride but more generally known as articaine hydrochloride, which bears US NIH Compound Identifier 32169. European Medicines Agency schedules Articaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00597MIG.

UNSPSC 51273606 Articaine hydrochloride is a Commodity code that captures pharmaceutical procurement by state and local governments, though recent activity under this specific code does not align with the narrow chemical compound named. State and local bodies soliciting under pharmaceutical-related codes are purchasing controlled substances, naloxone products, generic multi-source medications, and over-the-counter items through both direct contracts and cooperative purchasing agreements. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and vendor channels. Work solicited ranges from supply agreements with quarterly or fixed-term delivery schedules to exploratory market-intelligence gathering (RFI activity) that precedes formal pharmaceutical procurement strategy.

Geographic activity centers on Florida, Texas, and Minnesota, with Minnesota's multistate cooperative purchasing alliance (MMCAP) spanning multiple participating states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs and negotiated net pricing models outside traditional pharmacy benefit manager channels, and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers. Vendors responding to pharmaceutical procurements typically must certify FDA compliance, maintain specific insurance coverage including commercial general liability and professional liability, comply with drug supply chain security requirements, and submit detailed product information including National Drug Codes and pricing formatted for electronic data interchange.